scispace - formally typeset
A

Adam D. DeVore

Researcher at Duke University

Publications -  344
Citations -  9458

Adam D. DeVore is an academic researcher from Duke University. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 33, co-authored 261 publications receiving 5599 citations. Previous affiliations of Adam D. DeVore include Brigham and Women's Hospital & Yale University.

Papers
More filters
Journal ArticleDOI

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, +798 more
- 27 Oct 2018 - 
TL;DR: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events, and evidence-based glucagon-like peptide 1 receptor agonists should be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events.
Journal ArticleDOI

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

Eric J. Velazquez, +8 more
- 07 Feb 2019 - 
TL;DR: Among patients with heart failure with reduced ejection fraction who were hospitalized for acute decompensated heart failure, the initiation of sacubitril–valsartan therapy led to a greater reduction in the N‐terminal pro–B‐type natriuretic peptide concentration than enalapril therapy.
Journal ArticleDOI

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry

Stephen J. Greene, +14 more
- 24 Jul 2018 - 
TL;DR: Strategies to improve guideline-directed use of HFrEF medications remain urgently needed, and these findings may inform targeted approaches to optimize outpatient medical therapy.
Journal ArticleDOI

Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.

Kevin S. Shah, +8 more
- 14 Nov 2017 - 
TL;DR: Among patients hospitalized with HF, patients across the EF spectrum have a similarly poor 5-year survival with an elevated risk for cardiovascular and HF admission, which underscores the need to improve treatment of patients with HF.
Journal ArticleDOI

Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure.

Ankur Gupta, +10 more
- 12 Nov 2017 - 
TL;DR: Among fee-for-service Medicare beneficiaries discharged after heart failure hospitalizations, implementation of the Hospital Readmissions Reduction Program was temporally associated with a reduction in 30-day and 1-year readmissions but an increase in 30/day and1-year mortality.